Christina A. Eichstaedt

Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment

<i>SMAD5</i> as a novel gene for familial pulmonary arterial hypertension

Pulmonary hypertension in adults with congenital heart defects (ACHDs) in light of the 2022 ESC PAH guidelines—part II: supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management (shunt lesion, left ventricular disease, univentricular hearts), interventions, intensive care, ACHD follow-up, future perspective

Pulmonary hypertension in adults with congenital heart defects (ACHDs)—in light of the 2022 ESC PAH guidelines—part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects

Defining the clinical validity of genes reported to cause pulmonary arterial hypertension

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial

Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension

Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension

ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

First identification of<i>Krüppel-like factor 2</i>mutation in heritable pulmonary arterial hypertension

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension